Pharma Companies Have Increased MRP By 20-50 Per Cent Over The Past Six Months

Palanpur:  A sudden surge in the prices of life-saving drugs has left consumers reeling, as pharma companies have increased costs by 20-50 per cent over the past six months. Essential medications for hypertension, diabetes, cancer and common gastrointestinal ailments have reached new price highs, while the cost of antibiotics used in surgeries has nearly doubled.

Despite the applicability of the Essential Commodities Price Control Act in the state — which grants district magistrates authority to regulate and take action against price violations — there appears to be no enforcement against the profiteering of pharmaceutical companies.

Social activist Subhash Sharma highlighted shocking discrepancies in drug pricing. For instance, Pantoprazole-40 mg, prescribed for acidity, has an MRP of Rs 130 for a strip of 10 tablets, while its actual cost price is just Rs 20. This exposes profit margins exceeding 90 per cent, with some medications reportedly yielding profits of 1,000 per cent to 1,500 per cent for retailers. “This is only one example,” Sharma said, pointing out that similar price gouging affects hundreds of

In the absence of stringent checks, companies print exorbitant maximum retail prices (MRPs) on generic medicines, forcing poor patients to pay unjustified amounts. Many accuse administrative bodies and vigilance agencies of turning a blind eye, enabling pharmaceutical companies to exploit consumers.

A senior official from the state Drug Control Department admitted that state authorities have limited powers in this matter. “The Government of India has allowed pharma companies to print MRPs on all drugs, and only the Central Drug Controller can intervene,” the official stated.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices